Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial

Sarcomatoid hepatocellular carcinoma (SHCC) is a rare variant of liver cancer that lacks treatment options. The IMbrave trail demonstrated the efficacy of atezolizumab and bevacizumab (A + B) in patients with unresectable hepatocellular carcinoma but excluded patients with sarcomatoid variants. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Fencer, Maria G., Davis, Catherine H., Liu, Jieqi, Galan, Mark A., Spencer, Kristen R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791267/
https://www.ncbi.nlm.nih.gov/pubmed/36541195
http://dx.doi.org/10.1177/23247096221129470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791267/
https://www.ncbi.nlm.nih.gov/pubmed/36541195
http://dx.doi.org/10.1177/23247096221129470

Ejemplares similares